MedTrace Logo

Ketamine Infusions for PTSD and Treatment-Resistant Depression

NCT02577250 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-05-14

No results posted yet for this study

Summary

The relationship between depression and trauma is well established. Co-occuring depression and post-traumatic stress disorder (PTSD) are associated with more severe symptoms and lower levels of functioning. Veterans with both depression and PTSD have been shown to be at much higher risk of suicide than individuals with only one of these disorders. Ketamine has been shown to have rapid antidepressant effects and also therapeutic action over PTSD symptoms. The purpose of this study is to see whether ketamine, when given as repeated infusions, can produce quick and sustained improvement in depression and PTSD symptoms for individuals who have not had their symptoms effectively treated by current treatments.

Conditions

  • Depressive Disorder, Treatment-Resistant
  • Stress Disorders, Post-Traumatic

Interventions

DRUG

Ketamine

Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.

Sponsors & Collaborators

  • Minneapolis Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Paulo Shiroma, MD · Minneapolis Veterans Affairs Medical Center

  • Cristina S Albott, MD,MA · Minneapolis Veterans Affairs Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-06-30
Completion
2016-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02577250 on ClinicalTrials.gov